Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2021: Market was Valued at $3271.3 Million in 2020 - Forecast to 2026 [MarketWatch]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: MarketWatch
Dublin, Jan 20, 2022 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering. Global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share. The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment. The major factor
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Why AbbVie Stock Stumbled Today Despite the Earnings Beat [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View [Yahoo! Finance]Yahoo! Finance
- AbbVie's Q1: Positive Surprise [Seeking Alpha]Seeking Alpha
- AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- AbbVie Q1 report beats Street despite plunging Humira sales [Seeking Alpha]Seeking Alpha
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 4/26/24 - Form 8-K
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- ABBV's page on the SEC website